Biocept Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Biocept
BIOCQ Stock   0.0001  0.00  0.00%   
Analyzing historical trends in various income statement and balance sheet accounts from Biocept's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Biocept's valuation are summarized below:
Gross Profit
-14.3 M
Market Capitalization
262
Enterprise Value Revenue
0.0417
Revenue
1.4 M
Earnings Share
(48.17)
There are currently one hundred twenty fundamental signals for Biocept that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Biocept's prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/10/2026, Market Cap is likely to drop to about 3.3 M. In addition to that, Enterprise Value is likely to drop to about 2.4 M

Biocept Total Revenue

33.03 Million

Check Biocept financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocept's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 300.3 K or Selling General Administrative of 12.6 M, as well as many indicators such as Price To Sales Ratio of 0.13, Dividend Yield of 0.0 or PTB Ratio of 0.32. Biocept financial statements analysis is a perfect complement when working with Biocept Valuation or Volatility modules.
  
Build AI portfolio with Biocept Stock
Check out the analysis of Biocept Correlation against competitors.
To learn how to invest in Biocept Stock, please use our How to Invest in Biocept guide.

Biocept Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets43 M35.5 M26.8 M
Slightly volatile
Short and Long Term Debt Total10.9 M13.9 M6.6 M
Slightly volatile
Other Current Liabilities2.2 M2.6 M2.1 M
Slightly volatile
Total Current Liabilities7.1 M5 M6.4 M
Pretty Stable
Total Stockholder Equity9.7 M10.2 M12.9 M
Very volatile
Property Plant And Equipment Net12.8 M16.3 M8.2 M
Slightly volatile
Current Deferred Revenue0.80.90.9824
Slightly volatile
Accounts Payable1.3 M1.4 M2.5 M
Very volatile
Cash18 M14.8 M12.2 M
Slightly volatile
Non Current Assets Total13.2 M16.7 M8.3 M
Slightly volatile
Cash And Short Term Investments18 M14.8 M12.2 M
Slightly volatile
Net Receivables1.8 M1.9 M4.3 M
Very volatile
Common Stock Shares Outstanding418.4 K649.9 K255.3 K
Slightly volatile
Liabilities And Stockholders Equity43 M35.5 M26.8 M
Slightly volatile
Non Current Liabilities Total11 M19 M6.6 M
Slightly volatile
Capital Lease Obligations10.8 M13.8 M6.5 M
Slightly volatile
Inventory1.7 M870.5 K1 M
Slightly volatile
Other Current Assets675.3 K484.2 K486.9 K
Slightly volatile
Other Stockholder Equity317.7 M353.4 M279.6 M
Slightly volatile
Total Liabilities20.7 M25.3 M13.2 M
Slightly volatile
Net Invested Capital9.8 M10.3 M13 M
Very volatile
Property Plant And Equipment Gross18 M22.4 M12.8 M
Slightly volatile
Total Current Assets29.8 M18.8 M18.5 M
Slightly volatile
Capital Stock1.5 K2.3 K1.1 K
Slightly volatile
Net Working Capital20.1 M12.5 M11.9 M
Slightly volatile
Short Term Debt2.3 M2 M1.8 M
Slightly volatile
Common Stock2.2 K1.8 K4 K
Slightly volatile
Non Currrent Assets Other338.1 K347.4 K410.9 K
Slightly volatile
Short and Long Term Debt93.6 K105.3 K114.9 K
Slightly volatile
Non Current Liabilities Other4.9 M5.5 M6 M
Slightly volatile

Biocept Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.9 M1.1 M
Slightly volatile
Interest Expense300.3 K363.4 K272.8 K
Slightly volatile
Selling General Administrative12.6 M18.5 M10.1 M
Slightly volatile
Selling And Marketing Expenses7.6 M8.2 M6.5 M
Slightly volatile
Total Revenue33 M29.7 M16.7 M
Slightly volatile
Other Operating Expenses53.1 M66.5 M40.3 M
Slightly volatile
Research Development5.8 M7.1 M5.2 M
Slightly volatile
Cost Of Revenue27.1 M32.7 M18.5 M
Slightly volatile
Total Operating Expenses26 M33.8 M21.9 M
Slightly volatile
Reconciled Depreciation1.4 M1.9 M1.1 M
Slightly volatile

Biocept Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.1 M3.7 M1.6 M
Slightly volatile
Begin Period Cash Flow34.9 M33.2 M12.5 M
Slightly volatile
Depreciation1.7 M1.9 M1.2 M
Slightly volatile
Other Non Cash Items986.5 K567.9 K1.4 M
Slightly volatile
Capital Expenditures1.1 M928 K837.4 K
Slightly volatile
Issuance Of Capital Stock205.2 K216 K17.5 M
Slightly volatile
End Period Cash Flow18 M14.8 M12.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.130.11581.6 K
Slightly volatile
Days Sales Outstanding33.1734.92278
Slightly volatile
Average Payables4.9 M4.7 M2.9 M
Slightly volatile
Stock Based Compensation To Revenue0.140.124816.702
Slightly volatile
Capex To Depreciation0.670.440.7602
Pretty Stable
Inventory Turnover35.533.8122.2743
Slightly volatile
Days Of Inventory On Hand10.6111.1719.6889
Slightly volatile
Payables Turnover17.6516.818.0149
Slightly volatile
Sales General And Administrative To Revenue0.680.72311
Slightly volatile
Average Inventory495.1 K471.5 K372 K
Slightly volatile
Research And Ddevelopement To Revenue0.260.27998
Slightly volatile
Capex To Revenue0.03410.035933.2753
Slightly volatile
Cash Per Share24.9326.243.4 K
Slightly volatile
Days Payables Outstanding21.3522.482.6 K
Slightly volatile
Current Ratio1.512.671.9302
Slightly volatile
Receivables Turnover9.3713.828.8064
Pretty Stable
Capex Per Share1.561.64422
Slightly volatile
Average Receivables13.2 M12.6 M5.6 M
Slightly volatile
Revenue Per Share49.9952.62510
Slightly volatile
Interest Debt Per Share24.0225.2823.1 K
Slightly volatile
Debt To Assets0.430.452.2757
Slightly volatile
Operating Cycle43.7946.09295
Slightly volatile
Days Of Payables Outstanding21.3522.482.6 K
Slightly volatile
Ebt Per Ebit1.21.161.0896
Pretty Stable
Quick Ratio1.422.551.8275
Slightly volatile
Net Income Per E B T1.11.151.0131
Slightly volatile
Cash Ratio1.092.111.4242
Slightly volatile
Days Of Inventory Outstanding10.6111.1719.6889
Slightly volatile
Days Of Sales Outstanding33.1734.92278
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.091.221.0202
Pretty Stable
Fixed Asset Turnover1.031.651.2818
Slightly volatile
Debt Ratio0.430.452.2757
Slightly volatile
Price Sales Ratio0.130.11581.6 K
Slightly volatile
Asset Turnover0.790.750.4526
Slightly volatile

Biocept Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.3 M3.4 M13.3 M
Slightly volatile
Enterprise Value2.4 M2.5 M10.7 M
Slightly volatile

Biocept Fundamental Market Drivers

About Biocept Financial Statements

Biocept shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Biocept investors may analyze each financial statement separately, they are all interrelated. The changes in Biocept's assets and liabilities, for example, are also reflected in the revenues and expenses on on Biocept's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.80 
Total Revenue29.7 M33 M
Cost Of Revenue32.7 M27.1 M
Stock Based Compensation To Revenue 0.12  0.14 
Sales General And Administrative To Revenue 0.72  0.68 
Research And Ddevelopement To Revenue 0.27  0.26 
Capex To Revenue 0.04  0.03 
Revenue Per Share 52.62  49.99 
Ebit Per Revenue(1.11)(1.17)

Additional Tools for Biocept Stock Analysis

When running Biocept's price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY